Your browser is no longer supported. Please, upgrade your browser.
THTX Theratechnologies Inc. daily Stock Chart
Theratechnologies Inc.
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand76.95M Perf Week-1.47%
Market Cap207.00M Forward P/E- EPS next Y- Insider Trans- Shs Float75.73M Perf Month-5.94%
Income- PEG- EPS next Q- Inst Own- Short Float2.16% Perf Quarter-20.88%
Sales59.61M P/S3.47 EPS this Y- Inst Trans- Short Ratio15.29 Perf Half Y-35.02%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-57.06%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.60 - 7.14 Perf YTD-18.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.32% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low3.46% ATR0.13
Employees32 Current Ratio- Sales Q/Q19.10% Oper. Margin- RSI (14)44.94 Volatility3.59% 4.66%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.02 Prev Close2.71
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume106.76K Price2.69
Recom- SMA20-3.64% SMA50-5.98% SMA200-30.83% Volume108,674 Change-0.74%
Feb-18-20 08:00AM  Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019 GlobeNewswire
Feb-04-20 07:30AM  Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon GlobeNewswire
Dec-19-19 09:06AM  Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020 GlobeNewswire
Dec-13-19 07:30AM  Theratechnologies Oncology Platform Improves Efficacy and Tolerability of Docetaxel in Vivo and in Vitro GlobeNewswire
Oct-17-19 02:42PM  Does Theratechnologies Inc.'s (TSE:TH) CEO Salary Compare Well With Others? Simply Wall St.
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.